Ashvattha Therapeutics logo

Ashvattha Therapeutics Funding & Investors

Redwood City, CA

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel hydroxyl dendrimer (HD) therapeutics (HDTs) to treat unmet medical needs in oncology, ophthalmology, and inflammatory diseases.

avttx.com

Total Amount Raised: $148,000,000

Ashvattha Therapeutics Funding Rounds

  • Series B

    $50,000,000

    Series B Investors

    Tribe Capital
    Natural Capital
  • Series B

    $69,000,000

    Series B Investors

    Huadong Medicine
    Natural Capital Investment Fund
    Tribe Capital
    Plum Alley
  • Convertible Note

    $22,000,000

    Convertible Note Investors

    Natural Capital
    Sam Altman
    Philip Deutch
    Bhaskar Ghosh
    Kyle Wang
    Kingsley Advani
    Sakya Duvvuru
    Helios Capital
    Plum Alley
    Tribe Capital
    Sand Hill Angels
    Zephyr Venture Partners
  • Series A

    $7,000,000

    Series A Investors

    Natural Capital
    EcoR1 Capital
    Arjun Sethi
Funding info provided by Diffbot.